Exome Asset Management LLC Travere Therapeutics, Inc. Transaction History
Exome Asset Management LLC
- $115 Billion
- Q2 2024
A detailed history of Exome Asset Management LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Exome Asset Management LLC holds 443,379 shares of TVTX stock, worth $6.05 Million. This represents 3.17% of its overall portfolio holdings.
Number of Shares
443,379
Previous 362,487
22.32%
Holding current value
$6.05 Million
Previous $2.79 Billion
30.41%
% of portfolio
3.17%
Previous 2.39%
Shares
3 transactions
Others Institutions Holding TVTX
# of Institutions
184Shares Held
89.8MCall Options Held
137KPut Options Held
181K-
Black Rock Inc. New York, NY7.64MShares$104 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$102 Million0.8% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$101 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.62MShares$90.4 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.48MShares$61.2 Million1.14% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $876M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...